BSE Live
Mar 30, 16:01Prev. Close
386.55
Open Price
390.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 30, 15:56Prev. Close
386.15
Open Price
384.60
Bid Price (Qty.)
374.85 (84)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of SMS Pharmaceuticals (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 11.77 | 0.00 | |
| Net CashFlow From Operating Activities | 7.19 | 0.00 | |
| Net Cash Used In Investing Activities | -18.60 | 0.00 | |
| Net Cash Used From Financing Activities | 8.89 | 0.00 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -2.52 | 0.00 | |
| Cash And Cash Equivalents Begin of Year | 6.78 | 0.00 | |
| Cash And Cash Equivalents End Of Year | 4.26 | 0.00 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
01.04.2026
31.03.2026
31.03.2026
30.03.2026
Wockhardt novel antibiotic Zaynich gets thumbs-up from CDSCO expert panel
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth